TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Recommendation of “Hold” from Analysts

TScan Therapeutics, Inc. (NASDAQ:TCRX) has been given a consensus recommendation of “Hold” by the eight brokerages that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, five have given a hold recommendation and two have issued a buy recommendation on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $2.6667.

Several research firms have recently weighed in on TCRX. Weiss Ratings downgraded shares of TScan Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday. Benchmark reaffirmed a “buy” rating on shares of TScan Therapeutics in a research note on Thursday, August 13th. Wedbush downgraded shares of TScan Therapeutics from a “buy” rating to a “neutral” rating and set a $1.00 price objective for the company. in a report on Wednesday, September 2nd. HC Wainwright downgraded TScan Therapeutics from a “buy” rating to a “neutral” rating and set a $1.00 target price for the company. in a research note on Tuesday. Finally, Lifesci Capital lowered TScan Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 2nd.

TScan Therapeutics Price Performance

Shares of TCRX opened at $0.32 on Monday. The business’s 50-day moving average is $0.76 and its two-hundred day moving average is $0.96. The company has a market capitalization of $21.72 million, a P/E ratio of -0.35 and a beta of 1.07. The company has a debt-to-equity ratio of 0.31, a quick ratio of 3.37 and a current ratio of 3.37. TScan Therapeutics has a fifty-two week low of $0.31 and a fifty-two week high of $2.57.

TScan Therapeutics (NASDAQ:TCRX) last posted its earnings results on Wednesday, August 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.02. The firm had revenue of $1.05 million during the quarter, compared to analysts’ expectations of $1.88 million. TScan Therapeutics had a negative net margin of 1,655.35% and a negative return on equity of 108.72%. Research analysts predict that TScan Therapeutics will post -1.04 earnings per share for the current year.

Institutional Investors Weigh In On TScan Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TCRX. Goldman Sachs Group Inc. raised its holdings in TScan Therapeutics by 6.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 170,349 shares of the company’s stock valued at $235,000 after buying an additional 9,676 shares during the period. JPMorgan Chase & Co. increased its position in shares of TScan Therapeutics by 8.5% during the second quarter. JPMorgan Chase & Co. now owns 287,743 shares of the company’s stock valued at $417,000 after acquiring an additional 22,642 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of TScan Therapeutics in the 2nd quarter valued at approximately $78,000. Qube Research & Technologies Ltd purchased a new stake in shares of TScan Therapeutics in the 2nd quarter valued at approximately $99,000. Finally, Jane Street Group LLC acquired a new position in shares of TScan Therapeutics in the 2nd quarter worth approximately $309,000. Hedge funds and other institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.